RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Acer Therapeutics P/E 2024

Acer Therapeutics P/E

3.48

Acer Therapeutics Dividend yield

Ticker

ACER

ISIN

US00444P1084

WKN

A2DYQV

As of May 23, 2024, Acer Therapeutics's P/E ratio was 3.48, a -564% change from the -0.75 P/E ratio recorded in the previous year.

The Acer Therapeutics P/E history

Acer Therapeutics Aktienanalyse

What does Acer Therapeutics do?

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel drugs for rare and life-threatening diseases. The company was founded in 2017 and is headquartered in Cambridge, Massachusetts. The history of Acer Therapeutics began with an innovative strategy for rediscovering already approved drugs for new therapeutic applications. The company utilizes a "repurposing" technology, in which already approved drugs are reevaluated and further developed for the treatment of rare diseases. Acer Therapeutics' business model includes a combination of in-house research activities, strategic partnerships, and acquisitions. The company follows a portfolio strategy with a focus on rare diseases to develop a diversified pipeline of innovative medications. The various divisions of Acer Therapeutics focus on different therapeutic areas. Currently, the company is focused on the development of drugs for the treatment of rare anemia, severe lymphocytic leukemia, and narcolepsy. Acer Therapeutics' flagship product is EDSIVO, a medication for the treatment of arterial hypertension, a rare and life-threatening condition characterized by elevated blood pressure in the arteries. EDSIVO is currently approved in the United States and is under review in Europe. The company plans to further develop EDSIVO for the treatment of other rare diseases. Another important product of Acer Therapeutics is ACER-001, a medication for the treatment of the rare metabolic disorder urea cycle disorders. ACER-001 is an oral formulation of sodium phenylbutyrate and is intended to help patients regulate ammonia metabolism and alleviate symptoms. In recent years, Acer Therapeutics has also entered into several strategic partnerships and acquisitions to expand and strengthen its pipeline of rare diseases. In 2019, the company acquired biopharmaceutical specialist Celipheon, thereby expanding its portfolio to include drugs for the treatment of anemia and leukemia. Another important partner of Acer Therapeutics is Ultragenyx Pharmaceutical, a biopharmaceutical company specializing in the development of therapies for rare and ultra-rare diseases. The two companies have entered into a licensing agreement for ACER-001, in which Ultragenyx has exclusive rights for the commercialization of the medication in North America and Europe. Overall, Acer Therapeutics' business model and portfolio strategy have made it a key player in the rare disease sector. Through partnerships and acquisitions, it has expanded its pipeline and focused its research on various therapeutic areas. The company is currently in a growth phase and has the potential to bring more groundbreaking medications for rare diseases to the market in the future. Acer Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Acer Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Acer Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Acer Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Acer Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Acer Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Acer Therapeutics Stock

What is the price-to-earnings ratio of Acer Therapeutics?

The price-earnings ratio of Acer Therapeutics is currently 3.48.

How has the price-earnings ratio of Acer Therapeutics changed compared to last year?

The price-to-earnings ratio of Acer Therapeutics has increased by -564% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Acer Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Acer Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Acer Therapeutics affect the company?

An increase in the price-earnings ratio of Acer Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Acer Therapeutics affect the company?

A decrease in the price-earnings ratio of Acer Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Acer Therapeutics?

Some factors that influence the price-earnings ratio of Acer Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Acer Therapeutics pay?

Over the past 12 months, Acer Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Acer Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Acer Therapeutics?

The current dividend yield of Acer Therapeutics is .

When does Acer Therapeutics pay dividends?

Acer Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Acer Therapeutics?

Acer Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Acer Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Acer Therapeutics located?

Acer Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Acer Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Acer Therapeutics from 5/23/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/23/2024.

When did Acer Therapeutics pay the last dividend?

The last dividend was paid out on 5/23/2024.

What was the dividend of Acer Therapeutics in the year 2023?

In the year 2023, Acer Therapeutics distributed 0 USD as dividends.

In which currency does Acer Therapeutics pay out the dividend?

The dividends of Acer Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Acer Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Acer Therapeutics

Our stock analysis for Acer Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Acer Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.